BAJAJ BROKING
Biocon Biologics has received USFDA approval for Jobevne, a bevacizumab biosimilar used in cancer treatment. With US sales of bevacizumab reaching $2 billion in 2023, this approval expands Biocon’s oncology portfolio amid a competitive biosimilar market.
Biocon Ltd.’s subsidiary, Biocon Biologics, has received approval from the United States Food and Drug Administration (USFDA) for its cancer therapy drug Jobevne. This new biosimilar of bevacizumab is approved for intravenous use in the treatment of multiple types of cancer. The approval adds another high-value asset to Biocon Biologics' oncology product line in the US, alongside Ogivri and Fulphila. Jobevne targets vascular endothelial growth factor (VEGF), cutting off blood supply to tumours by inhibiting angiogenesis—a clinically proven mechanism in cancer therapy.
Also read: IndiGo Becomes World’s Most Valuable Airline With $23.4 Billion Market Cap
Biocon Biologics secures USFDA approval for Jobevne (bevacizumab biosimilar)
Jobevne becomes the seventh biosimilar from Biocon Biologics approved in the US
Adds to existing oncology portfolio in the US, including Ogivri and Fulphila
Bevacizumab biosimilars generated $2 billion in US sales in 2023
Biocon also markets bevacizumab in Europe and Canada under the name Abevmy
Also read: SRF Ltd. Commissions New Agrochemical Unit in Dahej Worth Rs.239 Crore
The USFDA nod for Jobevne strengthens Biocon Biologics' presence in the world’s largest pharmaceutical market. This milestone follows the company’s earlier launches of Ogivri (trastuzumab) and Fulphila (pegfilgrastim) in the oncology space. Jobevne’s approval allows Biocon Biologics to compete with major bevacizumab biosimilar producers in the US, such as Amgen, Amneal, Pfizer, and Celltrion. Given that US sales for bevacizumab alone touched nearly $2 billion last year, the entry of Jobevne positions the company favourably in a high-value, competitive market.
Drug Name | Reference Product | Use Case | Year of Approval |
Jobevne | Avastin | Cancer treatment | 2024 |
Ogivri | Herceptin | Breast cancer | 2017 |
Fulphila | Neulasta | Chemotherapy support | 2018 |
Despite the regulatory breakthrough, Biocon Ltd. share price ended Wednesday’s trading session lower at Rs.305.6, down 5.18%. So far in 2025, Biocon Ltd. share price has declined by 17.14%, reflecting broader market volatility and sectoral shifts. However, the latest approval is expected to lend long-term strength to Biocon Ltd. share price, as the oncology segment becomes a key revenue contributor in global markets.
With the USFDA approval of Jobevne, Biocon Biologics continues to enhance its oncology footprint in major global markets. The addition of this bevacizumab biosimilar reflects the company’s focus on expanding its pipeline of high-demand biologics. As oncology biosimilars gain traction, this regulatory success could help drive future revenue and reinforce Biocon Ltd. share price stability amid ongoing market movements.
Also read: Tata Motors’ JLR India Achieves Record Sales in FY25 at 6,183 Units
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading